Abstract
Objectives: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HFV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. Method: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromized individuals (500-200 CD4+ cells/mm3). Results: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. Conclusion: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.
Original language | English |
---|---|
Pages (from-to) | 293-298 |
Number of pages | 6 |
Journal | Journal of Human Virology |
Volume | 1 |
Issue number | 4 |
Publication status | Published - May 1998 |
Keywords
- AIDS
- Immunization
- Immunotherapy
- Tat protein
ASJC Scopus subject areas
- Virology